US FDA says Ranbaxy has to forfeit exclusivity for capsules to treat stomach and aesophagus problems

Published: 30-Jan-2015
Regulatory Pharmaceutical

US regulator revokes tentative approvals for two Ranbaxy generics


The US FDA has determined that the Indian drug manufacturer Ranbaxy forfeit its 180 days exclusivity for esomeprazole magnesium delayed release capsules used to treat stomach and aesophagus problems.

Ranbaxy says it is 'disappointed' with the result and is 'pursuing all available legal options to preserve its rights'.

In November 2014, the US regulator revoked its tentative approvals for Ranbaxy's generic anti viral drug valganciclovir hydrochloride and esomeprazole magnesium delayed release capsules 20mg and 40mg.

While the FDA said Ranbaxy's abbreviated new drug application (ANDA) did not have any data integrity issues, it added that its 'original decisions granting tentative approvals were in error, because of the compliance status of the facilities referenced in the ANDAs at the time the tentative approvals were granted'.

  • Companies:
  • Sun Pharmaceutical Industries
See more

You may also like

Finance

Sun Pharma to operate manufacturing plants in Japan

Read more
India's drugmaker taps into dermatology market with acquisition of Japan-based Pola Pharma

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Sun Pharma to operate manufacturing plants in Japan

India's drugmaker taps into dermatology market with acquisition of Japan-based Pola Pharma
Pharmaceutical

Sun Pharma opens new cGMP production line in India

The Mumbai-based company has installed a production line in Guwahati to enhance the manufacturing capacity of sterile products
Regulatory

Several large Indian pharma companies under US FDA scrutiny

Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Pharmaceutical

Sun Pharma launches generic version of Novartis' anti-leukaemia drug Gleevec in US

In 2015 the product had total sales of US$4.5bn globally and $2.5bn in the US, according to IMS data
Regulatory

Sun Pharma Global recalls osteoporosis drug in US

After an 'unknown purity' was discovered in cartons of alendronate sodium tablets
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Finance

Sun Pharmaceutical plans to purchase a portion of Novartis branded products in Japan

Will gain a foothold in Japan with speciality dermatology drugs anda portfolio of generics
Subscribe now